T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
A range of emerging therapeutic approaches for the treatment of cancer aim to induce or augment endogenous T cell responses. Chimeric antigen receptor (CAR) T cell therapy (CTT) is one such approach that utilises the patient’s own T cells, engineered ex vivo to target cell surface antigens, to elimi...
Guardado en:
Autores principales: | Palak H. Mehta, Salvatore Fiorenza, Rachel M. Koldej, Anthony Jaworowski, David S. Ritchie, Kylie M. Quinn |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aadff898576844feb5cfd0a605822392 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Joanne E. Davis, et al.
Publicado: (2021) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Sergey Kulemzin, et al.
Publicado: (2021) -
Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
por: Drokow EK, et al.
Publicado: (2019) -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
por: Hawkins ER, et al.
Publicado: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Cristina Aparicio, et al.
Publicado: (2021)